Rosiglitazone-induced changes in the oxidative stress metabolism and fatty acid composition in relation with trace element status in the primary adipocytes.

Publisher: Society of Medical Biochemists of Serbia Country of Publication: Serbia NLM ID: 101315490 Publication Model: Print Cited Medium: Print ISSN: 1452-8258 (Print) Linking ISSN: 14528266 NLM ISO Abbreviation: J Med Biochem Subsets: PubMed not MEDLINE

Publication: 2020- : Belgrade : Society of Medical Biochemists of Serbia
Original Publication: Belgrade : Society of Medical Biochemists of Serbia

Background: Metabolic syndrome, obesity and type 2 diabetes are metabolic disorders characterized by the insulin resistance and the impairment in the insulin secretion. Since impairment in the oxidative stress and adipocyte metabolism contribute to the formation of obesity and diabetes, targeting adipose tissue can be considered as an effective approach to fight against them. Rosiglitazone is used for treatment for patients with type 2 diabetes via inducing lipogenesis and transdifferentiation of white adipose tissue into brown adipose tissue. Since the development of such therapeutics is required to control the formation and function of brown fat cells, we aimed to reveal possible molecular mechanisms behind rosiglitazone induced biochemical changes in the adipose tissue.
Methods: Cells were expanded in the adipocyte culture medium supplemented with 5 µg/mL insulin following 2 days' induction. After those cells were treated with rosiglitazone 0, 0.13 mol/L and 10 µmol/L rosiglitazone for 48 hours and at 8th day, cells were collected and stored at -80 °C. Then the cells were used to evaluate antioxidant enzyme activities, mineral and trace element levels and fatty acid composition.
Results: Glucose-6-phosphate dehydrogenase and glutathione reductase significantly reduced in rosiglitazone-treated groups compared to the control. Na, Mg, K, Ca, Cr, Fe, Ni, Cu, Zn, Rb, Sr, Cs, Ba and Pb were determined in the cell lysates via ICP-MS. Also, relative FAME content decreased in the rosiglitazone-treated groups compared to the control.
Conclusions: Rosiglitazone treatment at low doses showed promising results which may promote brown adipose tissue formation.
Competing Interests: Conflict of Interest: The authors stated that they have no conflicts of interest regarding the publication of this article.
(2020 Duygu Aydemir, Ehsan Sarayloo, Ulusu Nuriye Nuray, published by CEON/CEES.)

Biol Trace Elem Res. 2018 Dec;186(2):474-488. (PMID: 29654488)
Nature. 2014 Sep 4;513(7516):100-4. (PMID: 25043053)
Prog Lipid Res. 2003 Jul;42(4):318-43. (PMID: 12689622)
Trends Endocrinol Metab. 2014 May;25(5):255-62. (PMID: 24731595)
Curr Ther Res Clin Exp. 2004 Jan;65(1):79-89. (PMID: 24936106)
Free Radic Res. 2010 Oct;44(10):1098-124. (PMID: 20836659)
FASEB J. 2010 May;24(5):1497-505. (PMID: 20032314)
Compr Physiol. 2013 Jan;3(1):1-58. (PMID: 23720280)
Diabetes. 2002 Aug;51(8):2412-9. (PMID: 12145152)
Hypertension. 1993 Jun;21(6 Pt 2):1024-9. (PMID: 8505087)
J Med Biochem. 2019 May 11;38(3):306-316. (PMID: 31156341)
Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E444-52. (PMID: 17473055)
Biomed Environ Sci. 2017 Jul;30(7):482-491. (PMID: 28756807)
Br J Nutr. 2016 Nov 9;:1-6. (PMID: 27825399)
J Toxicol Environ Health B Crit Rev. 2009 Mar;12(3):206-23. (PMID: 19466673)
Folia Biol (Praha). 2009;55(1):11-6. (PMID: 19445841)
J Biol Chem. 2003 Aug 29;278(35):33370-6. (PMID: 12807871)
Genes Dev. 2008 May 15;22(10):1269-75. (PMID: 18483216)
Cell. 2015 Feb 12;160(4):745-758. (PMID: 25662011)
Lipids. 2018 Jan;53(1):65-75. (PMID: 29424439)
Curr Diab Rep. 2010 Aug;10(4):306-15. (PMID: 20556549)
Toxicol Sci. 2014 Apr;138(2):468-81. (PMID: 24449420)
Diabetologia. 1995 Nov;38(11):1262-70. (PMID: 8582534)
Diabetes. 2002 Mar;51(3):797-802. (PMID: 11872682)
Biochim Biophys Acta. 1969 Jul 8;185(1):39-48. (PMID: 5796111)
Talanta. 2014 Oct;128:518-23. (PMID: 25059195)
Mol Cell Biol. 2003 Feb;23(3):1085-94. (PMID: 12529412)
IUBMB Life. 2012 May;64(5):362-9. (PMID: 22431005)
J Trace Elem Med Biol. 2017 Mar;40:46-53. (PMID: 28159221)
Endocrinology. 2002 Jun;143(6):2106-18. (PMID: 12021175)
J Clin Invest. 2004 Nov;114(9):1281-9. (PMID: 15520860)
J Biol Chem. 1995 Nov 24;270(47):28183-7. (PMID: 7499310)
Oxid Med Cell Longev. 2014;2014:360438. (PMID: 24999379)
Methods Enzymol. 1975;41:220-6. (PMID: 1128263)
J Biol Chem. 1974 Nov 25;249(22):7130-9. (PMID: 4436300)
J Clin Invest. 2005 Aug;115(8):2047-58. (PMID: 16075046)
J Biol Chem. 1997 Dec 26;272(52):32847-56. (PMID: 9407062)
J Agric Food Chem. 2012 Dec 5;60(48):11935-41. (PMID: 23140571)
Diabet Med. 2006 Oct;23(10):1050-6. (PMID: 16978367)
Mol Nutr Food Res. 2008 Jun;52(6):631-45. (PMID: 18306430)
Magnesium. 1985;4(2-3):60-72. (PMID: 2931560)

Keywords: fatty acid; minerals; oxidative stress; rosiglitazone; trace elements
Local Abstract: [Publisher, Serbian] Metabolički sindrom, gojaznost i dijabetes tip 2 su metabolički poremećaji za koje je karakteristična otpornost na insulin i poremećaj lučenja insulina. S obzirom da poremećaj oksidativnog stresa i metabolizma adipocita doprinosi gojaznosti i dijabetesa, ciljanje masnog tkiva se može smatrati efikasnim pristupom u borbi protiv njih. Rosiglitazon se koristi za lečenje pacijenata sa dijabetesom tipa 2 putem indukcije lipogeneze i transdiferencijacije belog masnog tkiva u mrko masno tkivo. Pošto je razvoj takvih terapija potreban za kontrolu stvaranja i funkcije mrkih masnih ćelija, želeli smo da otkrijemo moguće molekularne mehanizme koji stoje iza biohemijskih promena masnog tkiva izazvanih rosiglitazonom. [Publisher, Serbian] Ekspanzija ćelija je vršena u medijumu za adipocitnu kulturu dopunjenom sa 5 µg/mL insulina nakon indukcije od 2 dana. Nakon što su te ćelije tretirane rosiglitazonom 0, 0,13 mol/L i 10 µmol/L rosiglitazona tokom 48 sati, osmog dana ćelije su sakupljene i čuvane na -80 °C. Zatim su ćelije korišćene za procenu antioksidativnih enzimskih aktivnosti, nivoa mine rala i elemenata u tragovima i sastava masnih kiselina. [Publisher, Serbian] Glukoza-6-fosfat dehidrogenaza i glutation reduktaza su značajno smanjene u grupama tretiranim rosiglitazonom u poređenju sa kontrolom grupom. Na, Mg, K, Ca, Cr, Fe, Ni, Cu, Zn, Rb, Sr, Cs, Ba i Pb su određeni u ćelijskim lizatima preko ICP-MS. Takođe, relativni sadržaj FAME se smanjio u grupama tretiranim rosiglitazonom u poređenju sa kontrolom grupom. [Publisher, Serbian] Tretman rosiglitazonom u malim dozama pokazao je obećavajuće rezultate koji mogu pospešiti stvaranje mrkog masnog tkiva.

Date Created: 20210322 Latest Revision: 20220421

20221213

PMC7955996

10.2478/jomb-2019-0041

33746608